February 26, 2007
Medical Pioneer Dr. Emil Frei III to Head NEDAB Life Sciences Screening Committee
The Nevada Economic Development Advisory Board (NEDAB) announced the appointment of Dr. Emil Frei III to chair its Life Sciences Screening Committee. Dr. Frei will help identify growth-stage companies in the healthcare, medical devices, pharmaceutical and biotechnology industries that could potentially benefit from participation in capital markets to support their growth. Dr. Frei will also review business plans and conduct gap analysis to determine if prospective companies are candidates for NEDAB's support programs.
Dr. Frei is one of the world's leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career includes 40 years in top leadership positions such as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute (formerly Sidney Farber Cancer Institute). He continues as Physician-in-Chief, Emeritus, at Dana-Farber.
-- Senator Harry Reid -- Senator John Ensign -- Congresswoman Shelley Berkley -- Congressman Jon Porter -- Congressman Dean Heller -- Nevada Governor Jim Gibbons -- State Senator Barbara Cegavske on behalf of the Nevada Legislature -- Commissioner Rory Reid on behalf of Clark County -- Councilwoman Lois Tarkanian on behalf of the City of Las Vegas
Dr. Frei's appointment is the first of several planned industry screening chairs to be named by NEDAB. NEDAB is actively seeking screening committee chairs in the following industries:
-- Banking & Finance -- Business Services -- Construction, Property & Real Estate -- Energy -- Consumer Goods -- Engineering -- Industrial Equipment & Machinery -- Media -- Natural Resources -- Retailing -- Technology -- Telecommunications -- Tourism, Entertainment & Hospitality -- Transportation -- Utilities
"The industry chairs are an essential part of our strategy to support economic development in Nevada," said NEDAB spokesperson Robert Uithoven. "We feel that direct outreach into these industries and review of companies by qualified industry experts like Dr. Frei is the best way to find companies that can benefit from participation in the capital markets and drive economic development through their growth."
"I'm pleased to be undertaking this initiative," said Dr. Frei. "I'd like to extend an invitation to the local research institutions and other innovators in the fields of biotechnology, health care, medical equipment, pharmaceuticals and other life sciences to contact NEDAB and connect with me so that we may discuss how we may be able to assist you in bringing these worthy technologies to a larger market. Through participation in the capital markets, companies can raise funds and increase their market visibility."
About Emil Frei III, MD
Dr. Emil Frei III is one of the world's leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education.
He has been a major contributor to the successful application of chemotherapy, particularly the use of chemotherapeutic agents in combination for acute leukemia in children and in Hodgkin's disease and chemotherapy following surgical removal of the primary tumor in patients with the more common tumors including breast cancer and osteosarcoma. He produced major therapeutic advances in head and neck cancers. He has been particularly effective in applying the sciences of pharmacology, toxicology, clinical trial design and cytokinetics. Tens of thousands of patients have been cured by these treatments.
His contributions have been acknowledged by numerous awards including the Albert Lasker Award, the Kettering Prize from the General Motors Cancer Research Foundation and most recently the Inaugural Lifetime Achievement Award from the American Association for Cancer Research.
Dr. Frei's career in medicine began in 1948 after participating in the country's V-12 program of the Navy. He served in both WW II and the Korean War as a general physician including time on the battlefield. He then served at the National Institutes of Health (NIH) in the National Cancer Institute division as Chief of Medicine and was principal investigator in the leukemia research program.
He developed a reputation as a great institutional leader, particularly for his ability to secure funding and manage growing organizations. At M. D. Anderson in the late 1960s, he was instrumental in obtaining $1 million a year in operating funds from NIH for the development of cancer research programs. At the Farber Cancer Institute in the 1970s, he helped obtain a gift of $7 million from Charles A. Dana as seed money for partial construction of the institute's new permanent facility, and with the help of Massachusetts Senator Edward W. Brooke III, he was able to obtain the additional $10 million from NIH to complete construction.
He has been an industry leader, serving as past president of American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and CALGB clinical research group. He has also served on the advisory or director boards of numerous companies and non-profit organizations, including Adherex Technologies, Angstrom, CaP Cure, Celator Pharmaceuticals, DIAD Research, Immunogen, Vion Pharmaceuticals, Aid for Cancer Research, Cancer Research Institute, Journal of Clinical Oncology and the New England Journal of Medicine.
Dr. Frei has been a leader in medical education, serving as Professor of Medicine at The University of Texas from 1965-1972 and at Harvard Medical School from 1972-1996. He holds the chair of the Richard and Susan Smith Distinguished Professor of Medicine at Harvard, established through a $3 million gift from philanthropists Michael Milken, Marvin Davis and Edward Bennett Williams to fund oncology research.
He has directed the education of over 300 oncologists, many of whom have become today's top leaders and researchers, and has lectured to thousands. Together with Dr. James Holland, Dr. Frei co-authored the first text in medical oncology, Cancer Medicine, the seventh edition of which is primary standard text of the field.
Retired from full-time practice, Dr. Frei now lectures, writes and offers consulting services in areas including grant applications and reviews, clinical trials, industry collaboration and management advice.
For more information, visit http://www.Emil-Frei-III-MD.org.
About Nevada Economic Development Advisory Board (NEDAB)
NEDAB is a council of prominent businesspeople and legislators who share a vision of diversified economic growth through capital marketing participation and assist in making that vision a reality. NEDAB believes that Nevada has the potential to become the premier destination in the U.S. for small business issuers looking to enter the capital markets; that Nevada corporations across a variety of industries can benefit from participating in the capital markets as a way to build long-term shareholder value, provide access to capital, increase visibility and improve business practices to meet the standards of being a public company; and that an increased number of Nevada corporations successfully entering and sustaining participation in the capital markets will create diversified economic growth, increase the number of companies that physically relocate to Nevada, create new jobs and increase revenue for the state.
Activities of NEDAB include:
-- Outreach to other economic development groups, legislators, regulators, business owners, and business and industry leaders. -- Educational Programs for companies seeking to learn about capital markets and the advantages of domiciling in Nevada as a private or public company. -- Policy Research and Recommendations to make Nevada even more attractive as a home for companies wanting to participate in capital markets. -- Locally based Industry Screening Committees to help identify and screen companies that are good candidates for participation in the public markets.
NEDAB is in the process of expanding to its target of 10 members. Current members include:
-- Mark Daigle, NEDAB Co-Chairman and President and CEO of Colonial Bank N.A.'s Nevada operations. -- Paul Henry, Esq., President and CEO of Henry & Associates, LLC -- Robert Uithoven, President of J3 Strategies and Manager for Jim Gibbons' successful 2006 gubernatorial campaign.
Advisors to NEDAB include:
-- Bob Beers, State Senator District 6 & PCMC Nevada Client Audit Coordinator -- Tim Carlson, CEO of Powered by Renewables and Former Executive Director of Nevada Development Authority & Nevada Commission on Economic Development
For more information about NEDAB visit http://www.Nevada-EDAB.com.
NEDAB is a program of Public Company Management Corporation (OTCBB: PUBC). For more information about Public Company Management Corporation visit http://www.PublicCompanyManagement.com.
Contact: Robert Uithoven NEDAB Spokesperson Phone: (775) 762-8550 Contact via http://www.marketwire.com/mw/emailprcntct?id=332511FF1B2A0291 http://www.Nevada-EDAB.com
SOURCE: Public Company Management Corporation